Global Research Antibodies Analysis Report 2024: Emerging Opportunities with Expansion into Emerging Countries and Development of Novel Research Antibodies - Forecasts to 2028
17 janv. 2024 04h23 HE
|
Research and Markets
Dublin, Jan. 17, 2024 (GLOBE NEWSWIRE) -- The "Global Markets for Research Antibodies" report has been added to ResearchAndMarkets.com's offering. The global market for research antibodies was...
Global Antibody Hit Generation and Screening Market Analysis and Forecast 2023-2032 - Creative Biolabs, F. Hoffmann-La Roche, WuXi AppTec & ICOS Therapeutics Dominate the Market
15 janv. 2024 04h48 HE
|
Research and Markets
Dublin, Jan. 15, 2024 (GLOBE NEWSWIRE) -- The "Global Antibody Hit Generation and Screening Market: Analysis and Forecast, 2023-2032" report has been added to ResearchAndMarkets.com's offering.The...
Global $16.2B Research Antibodies & Reagents Market by Product, Technology, Application, End User & Region - Forecast to 2028
10 janv. 2024 09h38 HE
|
Research and Markets
Dublin, Jan. 10, 2024 (GLOBE NEWSWIRE) -- The "Research Antibodies & Reagents Market by Product (Antibodies (Type, Form, Source, Research Area), Reagents), Technology (Western blot, Flow...
Global Antibody Therapeutic Market Research Report 2024-2033 Featuring Key Players - AbbVie, Amgen, Johnson & Johnson Services, Eli Lilly and Co, and Hoffmann-La Roche
05 janv. 2024 04h53 HE
|
Research and Markets
Dublin, Jan. 05, 2024 (GLOBE NEWSWIRE) -- The "Global Antibody Therapeutic Market: Focus on Format, Disease Area, Route of Administration, End Users, Region, and Competitive Landscape - Analysis and...
Antivenom Global Market Report 2023
04 janv. 2024 16h38 HE
|
Research and Markets
Dublin, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The "Antivenom Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.Antivenom, also known as antivenin, is an antibody...
Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
02 janv. 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
SOLIRIS Drug Insight and Market Forecasts, 2032: Focus on 7 Major Markets - United States, Germany, France, Italy, Spain, United Kingdom, and Japan
07 déc. 2023 09h43 HE
|
Research and Markets
Dublin, Dec. 07, 2023 (GLOBE NEWSWIRE) -- The "SOLIRIS Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides comprehensive...
Global Antibody Collaboration and Licensing Agreement Analysis Report 2023 with Directory of 1,812 Deals Signed Since 2016
17 nov. 2023 06h43 HE
|
Research and Markets
Dublin, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The "Antibody Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.This report contains a comprehensive...
In Silico Drug Discovery Market Size Worth USD 11.68 Billion in 2032 | Emergen Research
15 nov. 2023 12h22 HE
|
Emergen Research
Vancouver, Nov. 15, 2023 (GLOBE NEWSWIRE) -- The global In Silico Drug Discovery Market is forecasted to be worth USD 11.68 Billion by 2032, according to a current analysis by Emergen Research. The...
Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
08 nov. 2023 16h00 HE
|
Dyadic International, Inc.
Received an upfront payment of $0.6 million in October for product development and licensing of our Dapibus™ platform for animal-free dairy enzyme productsDYAI-100 Phase 1 clinical trial top-line...